Wall Street analyst estimates for Entrada Therapeutics, Inc. (TRDA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (1-5) | 0.67 |
Valuation Ratios
| Price / Book | 1.22 |
| EV / EBITDA | -1.37 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | $129.0M | $210.8M | $25.4M |
| Cost of Revenue | $104000 | $326000 | 0 | 0 | 0 | 0 | $4.1M |
| Gross Profit | -$104000 | -$326000 | 0 | 0 | $129.0M | $210.8M | $21.3M |
| Research & Development | $8.2M | $21.1M | $35.9M | $66.6M | $99.9M | $125.3M | $142.3M |
| Selling, General & Admin | $3.6M | $5.2M | $15.2M | $30.6M | $32.3M | $38.5M | $41.0M |
| Operating Expenses | $11.8M | $26.3M | $51.1M | $97.2M | $132.2M | $163.8M | $177.3M |
| Operating Income | -$11.8M | -$26.7M | -$51.1M | -$97.2M | -$3.2M | $47.0M | -$156.0M |
| EBITDA | -$11.7M | -$26.2M | -$50.0M | -$90.1M | $14.9M | $70.3M | -$142.4M |
| Interest Expense | 0 | 0 | 0 | $2.6M | 0 | 0 | 0 |
| Pre-tax Income | -$5.1M | -$26.5M | -$51.2M | -$94.6M | $12.1M | $66.5M | -$142.8M |
| Income Tax | 0 | 0 | 0 | 0 | $18.7M | $859000 | $924000 |
| Net Income | -$4.6M | -$26.5M | -$51.2M | -$94.6M | -$6.7M | $65.6M | -$143.8M |
| EPS | $-4.44 | $-0.84 | $-1.60 | $-2.79 | $-0.20 | $1.76 | $-3.47 |
| EPS (Diluted) | $-4.44 | $-0.84 | $-1.60 | $-2.79 | $-0.20 | $1.68 | $-3.47 |
| Shares Outstanding (Diluted) | $1.0M | $31.2M | $31.2M | $31.3M | $33.1M | $39.0M | $41.4M |
Price
| Price | $6.89 |
| Market Cap | $267M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACHV · ALLO · ARCT · AVIR · CAPR · HUMA · IMRX
Explore sector: Healthcare · Biotechnology
More sections of TRDA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks